Stephen Kilfeather, PhD, CEO and Co-founder
Stephen Kilfeather is co-inventor of Aeirtec’s novel proteomics platform and inventor of the dual antibody affinity state-derived high sensitivity assay saspect within the platform; with all aspects being patent awarded across USA, EU and China. He has over 30 years experience in translational immune and inflammatory cell and clinical pharmacology and 10 years experience in translational cardiovascular research. He was a consultant in phase 2 respiratory anti-inflammatory clinical trial biomarker design for Astra Zeneca, Novartis and Boehringer Ingelheim and Principle Investigator on anti-inflammatory clinical trials for Boehringer Ingelheim, GSK and Altana in phase 2-4 trials. Through direction of a Site-Management Organisation for conduct of anti-inflammatory clinical trials, he also generated a platform for acquisition of human inflammatory disease tissue for conduct of immunopharmacology. In collaboration with Dr Elaine Lee, he established the essential role of leukotrienes in innate immune cell survival leading to biomarker design in phase 2 anti-inlfammatory leukotriene antagonist trials. He directed the evolution of blood biomarker multiplexing within Aeirtec, leading to stratification within several immune-related disorders with respect to severity and response to treatment through combined high sensitivity blood biomarker multiplexing and multivariate analyses. He has authored or co-authored over 40 peer reviewed publications and reviews. He received BSc and PhD in pharmacology from University of London.
Elaine Lee, PhD, CSO and Co-founder
Dr Elaine Lee is co-inventor of Aeirtec’s novel proteomics platform and oversaw its optimization to the point of production. Dr Lee also manages immunological research within Aeirtec. Dr Lee has project managed within preclinical and clinical anti-inflammatory drug development for multiple biotech and large pharma organisations. She has 25 years experience in directing immune-inflammatory cell pharmacology, managing clinical trials and blood biomarker multiplexing. Aeirtec’s proteomics technology has been applied under her management in conjunction with multivariate statistics to delineate disease pathology, patient group stratification and proteomic signatures of treatment response within Aeirtec. She established the critical role of leukotrienes in human innate immune cell survival and its reflection in cell-specific inflammatory cell apoptosis induction by the different leukotriene inhibitor drug classes. She received a BSc in pharmacology from the University of East London and PhD in pharmacology from University of Sunderland.